Volociximab
Encyclopedia
Volociximab is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec
for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin
.
It is thought to reduce metastases. Early results show potential in renal cell cancers.
[ref needed]
Biogen Idec
Biogen Idec, Inc. is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen Inc. and San Diego, California-based IDEC Pharmaceuticals...
for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin
Integrin
Integrins are receptors that mediate attachment between a cell and the tissues surrounding it, which may be other cells or the ECM. They also play a role in cell signaling and thereby regulate cellular shape, motility, and the cell cycle....
.
It is thought to reduce metastases. Early results show potential in renal cell cancers.
[ref needed]